Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT04141605

Global Utilization And Registry Database for Improved heArt preservatioN

The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the SherpaPak CTS System. These results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Heart Diseases Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Heart Defects, Congenital Heart Failure

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Graz, Graz, Austria

Loading trial locations.

About this study

This study is a registry study collecting data both retrospectively from patients already transplanted and prospectively from consecutively enrolled patients for heart transplantation. The study is a chart review study.

Ongoing eligible recipients will undergo heart transplantation according to standard practices at each participating institution.

This study will be conducted at an estimated 25 institutions globally and will have about up to 3000 patients. Subjects will be followed from transplant through one-year post-transplantation (i.e., 24 hours post-transplant, discharge, 30-days, 1-year, 2-years, 3-years, 4-years, 5-years).

GUARDIAN provides critical and contemporary data on patient outcomes, with additional insight into risk factors and patient-related indices. Both donor and recipient information along with procedural details (including transportation) will be collected to provide information for major discrete endpoints such as death, primary graft dysfunction, right ventricular dysfunction, CPB weaning, Inotrope use, CAV diagnosis, rejection, and survival.

Information about re-hospitalizations and re-transplantations is vital to address the integrated endpoint of days alive out of hospital, which is particularly relevant for this patient population. In addition, the number of in-hospital days and ICU time is closely tracked as the major resource utilized, after the initial transplant.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Donor and donor hearts matched to the prospective recipient based upon institutional medical practice
  • Registered male or female primary heart transplant candidates including pediatric candidates

Exclusion criteria

  • Donor and donor hearts that do not meet institutional clinical requirements for transplantation
  • When safe connection with the aorta cannot be made, e.g., due to lack of enough length of the aortic root
  • Patients who are incarcerated persons (prisoners)
  • Patients who have had a previous organ transplant

Treatment and study plan

SherpaPak Cardiac Transport System

Device

The Paragonix SherpaPak Cardiac Transport System ("SherpaPak CTS") is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.

The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached.

Other names: SherpaPak CTS

Primary outcomes

  1. Number of Patients with Primary Graft Dysfunction

    Time frame: one year

    Less than 40% LVEF by echocardiography or hemodynamics with RAP greater than 15 mm Hg, PCWP greater than 20 mm Hg, CI less thann 2 L/min/m^2, hypotension with MAP less than 70 mm Hg (lasting more than 1 hour)

  2. Number of Patients with Right Ventricular Dysfunction

    Time frame: one year

    hemodynamics with RAP grater than 15mm Hg, PCWP less than 15 mm Hg, CI less than 2 L/min/m^2, TPG less than 15mm Hg/pulmonary artery systolic pressure less than 50 mmHg OR need for RVAD

  3. Length of ICU Stay

    Time frame: one year

    Length of time patient admitted to the intensive care unit post transplant

  4. Length of Hospital Stay

    Time frame: one year

    Length of time before patient is discharged from the hospital post transplant

  5. Survival

    Time frame: 5 years

    The length of patient survival up to 5 years will be compared

Secondary outcomes

  1. Hospitalizations

    Time frame: one year

    Number of related hospitalizations post transplant

  2. CAV development

    Time frame: five years

    Number of patients who developed CAV between 1 and 5 years post transplant will be compared

  3. Retransplant

    Time frame: five years

    The number of patients who were retransplanted will be compared

Sponsors and collaborators

Lead sponsor

Paragonix Technologies

Industry

Registry information

Acronym: GUARDIAN

Important dates

Study start
2020
Primary completion
2027
Study completion
2029
First posted
Oct 28, 2019
Registry last updated
May 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.